Report Date: Wednesday, July 29, 2026 (before market open) | Call: 2026Q2 Earnings Call
BSX enters this print in one of the more damaged technical and sentiment positions among large-cap medtech names. The stock has fallen from roughly $95 in early January 2026 to the mid-$40s heading into earnings — a decline of more than 50% — driven by a string of guidance cuts and negative commentary over the past six months. Sentiment is negative, with the stock experiencing a sharp decline in recent months as growth expectations have cooled due to headwinds in electrophysiology, Watchman, and urology, along with Farapulse share loss. The Street is modeling organic revenue growth of 5.3% with EPS of 83 cents for the quarter — which sits within management's own guidance range.
February 4, 2026 (Q4/FY25 results): BSX capped off a strong 2025 — full year 2025 net sales of $20.074 billion, growing 19.9 percent on a reported basis, 19.2 percent on an operational basis and 15.8 percent on an organic basis — but issued initial 2026 guidance that already implied a sharp deceleration: the company estimated net sales growth for the full year 2026 to be approximately 10.5 to 11.5 percent on a reported basis and 10.0 to 11.0 percent on an organic basis, with adjusted EPS of $3.43 to $3.49. The stock fell hard on this de-rating even though results beat.
April 22, 2026 (Q1 2026 results): Management delivered a solid quarter — total company organic sales growth of 9.4% versus guidance of 8.5% to 10%, adjusted EPS of $0.80 grew 6%, achieving the high end of guidance of $0.78 to $0.80 — but then cut full-year guidance materially. 2026 has proven to be a more challenging year than initially expected, guiding to organic growth of 5% to 7% for the second quarter and reducing full year guidance to 6.5% to 8%, with full year adjusted EPS now expected at $3.34 to $3.41, representing growth of 9% to 11%. CEO Mike Mahoney was candid about the setback: "this is a guide down that we, quite frankly, are not proud of, but we think it's the right thing to do." Management attributed the cut to three factors: a decelerating trend in WATCHMAN standalone volumes that emerged in February, greater-than-expected EP/Farapulse share erosion despite a strong quarter, and continued underperformance in Urology (stone management and sacral neuromodulation).
May 27, 2026 (Bernstein conference): Sentiment deteriorated further after management flagged incremental WATCHMAN weakness intra-quarter. BSX stock plunged 12.46% to $50.38, becoming the worst performer in the S&P 500, after CEO Michael Mahoney flagged declining demand for Watchman stand-alone procedures. Mahoney attributed the drop to competitive pressures and workflow challenges, and said the company expects flat dollar growth from first quarter to second quarter, and likely in the third quarter, while reiterating full-year organic revenue growth of 6.5% to 8% (already down from the 10-11% initially guided).
July 21/27, 2026 (Restructuring announcement, days before earnings): Just before reporting, BSX pre-announced a major cost action. The Board approved a new global restructuring program intended to drive sustained cost efficiencies and enable continued growth, with key activities including supply chain optimization, transferring production lines among facilities, and organizational structure evolution, expected to be substantially completed by the end of 2029. The plan is estimated to result in total pre-tax charges of approximately $700-800 million, of which $600-700 million is expected to be cash, and reduce gross annual pre-tax expenses by approximately $500 million, with a substantial portion of savings expected to be reinvested in strategic growth initiatives. This is best read as management pulling a lever to defend margins/EPS as top-line growth has repeatedly disappointed — a signal worth watching for tone on the call.
a) WATCHMAN — has stand-alone stabilized? This has been the single biggest swing factor. Management's framework: global WATCHMAN grew 19% in Q1, below expectations, with pressure on volumes in the U.S. as the quarter progressed — reflecting annualization of the concomitant adoption tailwind and softening stand-alone cases tied to hospital capacity, procedure prioritization, and reimbursement dynamics. Full-year guide is now mid-teens global growth, but the sequential dollar trajectory (flat Q1-to-Q2, per the May comments) is the number to watch. CHAMPION trial data was positioned as the long-term catalyst, but it just takes time to disseminate data and educate physicians, and to translate into label/guideline/NCD updates.
b) EP/Farapulse — is share loss stabilizing? Management guided global EP to grow approximately 10% in 2026, with U.S. growth revised to mid-single-digit and international growth at plus-20%, acknowledging increased competition from Medtronic, J&J's enhanced PFA footprint, and Abbott's early-stage U.S. launch. Investors will want confirmation that U.S. EP has stabilized rather than continuing to erode, and updates on FARAWAVE Ultra, Faraflex and mapping-platform attach rates.
c) Urology — turnaround progress Urology grew just 1% organically in Q1, driven by weakness in stone management and sacral neuromodulation, with management citing too much commercial turnover over the prior 6-9 months in the SNM sales force. Watch for commentary on new rep hiring/training progress and new product launches (Asurys, slim ureteroscope).
d) Margins and EPS defense With top-line growth cut roughly in half from original guidance, the story shifts to cost control. Management still expects full year 2026 adjusted operating margin expansion of 50 to 75 basis points, though gross margin is now expected to be slightly below 2025 due to lower mix benefit. The newly announced $700-800M restructuring program will be a major topic — investors should listen for how much of the ~$500M in savings flows to 2026/2027 EPS versus reinvestment.
e) Capital allocation / Penumbra BSX's Board approved an additional $4 billion buyback authorization, bringing total authorization to $5 billion, and management intended to repurchase approximately $2 billion of shares in Q2 — a signal of confidence at depressed prices. The pending ~$15B Penumbra acquisition (thrombectomy/neurovascular) remains excluded from guidance and was expected to close in H2 2026, pending shareholder and regulatory approval; an update on timing and any financing considerations given the stock's decline would be notable.
BSX heads into this print as a battered growth stock trying to prove that its 2026 de-rating has bottomed. The bar for the quarter itself is relatively low (mid-single-digit organic growth, EPS in line with a guidance range management just set weeks ago), but the bar for the stock is really about the qualitative narrative: is WATCHMAN standalone stabilizing, is EP share loss plateauing, and can cost discipline (including the newly announced restructuring) protect the double-digit EPS growth algorithm that has been central to the bull case. Given the magnitude of the year-to-date decline, even an in-line quarter with confident, credible commentary on these fronts could trigger a relief rally, while any further deterioration — especially another guidance cut — would likely renew pressure on the stock.